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ABSTRACT: Studying metal-protein interactions is key for under-
standing the fate of metallodrugs in biological systems. When a metal
complex is not emissive and too weakly bound for mass spectrometry
analysis, however, it may become challenging to study such interactions.
In this work a synthetic procedure was developed for the alkyne
functionalization of a photolabile ruthenium polypyridyl complex,
[Ru(tpy)(bpy)(Hmte)](PF6)2, where tpy = 2,2′:6′,2′′-terpyridine, bpy
= 2,2′-bipyridine, and Hmte = 2-(methylthio)ethanol. In the function-
alized complex [Ru(HCC-tpy)(bpy)(Hmte)](PF6)2, where HCC-tpy =
4′-ethynyl-2,2′:6′,2′′-terpyridine, the alkyne group can be used for bioorthogonal ligation to an azide-labeled fluorophore using
copper-catalyzed “click” chemistry. We developed a gel-based click chemistry method to study the interaction between this
ruthenium complex and bovine serum albumin (BSA). Our results demonstrate that visualization of the interaction between the
metal complex and the protein is possible, even when this interaction is too weak to be studied by conventional means such as UV−
vis spectroscopy or ESI mass spectrometry. In addition, the weak metal complex-protein interaction is controlled by visible light
irradiation, i.e., the complex and the protein do not interact in the dark, but they do interact via weak van der Waals interactions after
light activation of the complex, which triggers photosubstitution of the Hmte ligand.
■ INTRODUCTION
Cytotoxicity assays, cell uptake studies, and cell fractionation
experiments are typically performed to investigate the
biological effects and the intracellular fate of metal-based
anticancer compounds.1−4 In addition, experiments regarding
the interactions of the metallodrug with isolated biomolecules
provide important insights about possible targets and binding
sites. A frequently studied protein in bioinorganic chemistry is
serum albumin. It is the most abundant protein in the
bloodstream (35−50 g/L) and thus a highly likely binding
partner for injected metallodrugs.5−7 Serum albumin is
responsible for the transport of biomolecules,8 can act both
as drug carrier and reservoir,9−13 and might support drug
accumulation in tumor cells.9 It has, however, been
demonstrated that interaction of anticancer drugs with serum
albumin can cause undesired side effects9,14 and hinder the
interaction with the actual targets of the drug.15 Bovine serum
albumin (BSA) is a model protein for human serum albumin
(HSA),13 with which it shares 76% of sequence homology,16
and it is a major component of cell-growth medium used for in
vitro studies.
Common methods to investigate metallodrug−protein
interactions are X-ray diffraction analysis,14,17,18 electrospray
ionization mass spectrometry (ESI-MS),19,20 inductively
coupled plasma optical emission spectrometry (ICP-OES)21
or mass spectrometry (ICP-MS),22 UV−vis spectroscopy,23
circular dichroism (CD) spectroscopy,24 tryptophan fluores-
cence spectroscopy,25−28 (nano)liquid chromatography,29,30
gel electrophoresis,31−33 capillary electrophoresis34,35 or
NMR.36−38 For emissive metallodrugs, the metal complex
and hence its interaction with biomolecules can be imaged on
gel electrophoresis or in cells by emission microscopy.39,40 For
the nonemissive metallodrugs considered here, however, this
approach is ineffective. In organic chemical biology a well-
developed method to visualize interaction between proteins
and nonemissive organic inhibitors is based on bioorthogonal
chemistry.41 In this approach, the drug is modified with a small
abiotic group42,43 and subsequently reacted with a fluorophore
via for example the Cu(I)-catalyzed azide−alkyne cyclo-
addition (CuAAC).44−48 For metal complexes, however, this
method is quite challenging, as it requires the modification of
the complex with an azide or alkyne click handle. For
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photosubstitutionally active polypyridyl ruthenium complexes
in particular, the preparation of such functionalized analogues
is a well-known synthetic challenge: Azide-functionalized
ruthenium complexes are known to be unstable,49,50 and
alkynes can act as ligands for ruthenium,51 leading to the
formation of many byproducts.52 So far, silver-based synthetic
routes have been developed toward alkyne-functionalized
ruthenium complexes, where silver(I) salts are used to either
enhance ligand exchange49 or to remove alkyne protecting
groups.53 Silver ions, however, are bioactive, and metallodrugs
synthesized according to silver-based synthetic procedures may
contain traces of silver that would modify their biological
properties.54
In this work, we aimed at developing a silver-free synthetic
route toward a ruthenium polypyridyl complex functionalized
with a terminal alkyne group and to use such complexes to
study metallodrug-serum albumin interactions on a gel using
CuAAC. The complex to functionalize, [Ru(tpy)(bpy)-
(Hmte)](PF6)2 ([1](PF6)2, Figure 1), where tpy =
2,2′:6′,2″-terpyridine, bpy = 2,2′-bipyridine, and Hmte = 2-
(methylthio)ethanol, is a typical example of a photosubstitu-
tionally active ruthenium(II) complex. This complex is
structurally similar to ruthenium-inhibitor conjugates recently
developed for photoactivated chemotherapy (PACT).55 PACT
consists of controlling the biological activity of a metal
complex by selective light irradiation of the diseased
tissue.56−58 Molecularly speaking, PACT works as follows:59,60
In the dark, coordination interactions of the metal with
biomolecules is prevented by the coordinated thioether
(Hmte) ligand. After photosubstitution of Hmte by a solvent
molecule, however, coordination of the activated drug to
biological molecules becomes possible. Although for DNA this
concept has been demonstrated repeatedly,61 to our knowledge
controlling with light the binding of a metal complex to
proteins has not yet been thoroughly investigated. Critically,
substitutionally active ruthenium complexes used in PACT
(e.g., [1]2+) are typically nonemissive because the triplet metal-
to-ligand charge transfer (3MLCT) excited states responsible
for the phosphorescence in, e.g., [Ru(bpy)3]2+ are quenched by
the low-lying, dissociative triplet metal-centered excited states
(3MC) that precisely allow photosubstitution to occur. As a
consequence, the light-controlled binding of PACT metal
complexes to biomolecules can neither be followed by
emission spectroscopy on gels nor by in vitro cell imaging.62
To solve this problem, a synthetic route toward [Ru(HCC-
tpy)(bpy)(Hmte)](PF6)2 ([2](PF6)2, HCC-tpy = 4′-ethynyl-
2,2′:6′,2″-terpyridine, Figure 1), the alkyne-functionalized
analogue of [1](PF6)2, was developed. The alkyne group was
then used as a click handle to study the interaction between
[2](PF6)2 and BSA, in the dark and after light irradiation, by
fluorophore labeling on a gel using CuAAC (Scheme 1). This
method was finally compared with two known methods for
studying BSA-metallodrug interaction, i.e., UV−vis spectros-
copy and ESI-MS.
■ EXPERIMENTAL SECTION
Synthesis. 4′-Bromo-2,2′:6′,2″-terpyridine and 2,2′-bipyridine
were purchased from TCI Europe, RuCl3 was purchased from Alfa
Aesar, 2-(methylthio)ethanol and tert-butyldimethylsilylethyne were
purchased from Sigma-Aldrich. [1](PF6)2 was synthesized according
to the literature.62 All metal complexes were synthesized in dim light
and stored in darkness. All commercial reactants and solvents were
used without further purification. 1H NMR spectra were recorded on
a Bruker AV-300 spectrometer. Chemical shifts are indicated in ppm.
Mass spectra were recorded by using an MSQ Plus Spectrometer. For
the proton attribution scheme, see the SI.
RCC-tpy (R = TBDMS). RCC-tpy was synthesized using an
adapted literature procedure.52 To dry and degassed triethylamine (12
mL) were added under a dinitrogen atmosphere 4′-bromo-2,2′:6′,2″-
terpyridine (1.0 g, 3.2 mmol), copper(I) iodide (38 mg, 0.20 mmol),
dichlorobis(triphenylphosphine)palladium (70 mg, 0.10 mmol), and
tert-butyldimethylsilylethyne (1.0 mL, 5.3 mmol). The reaction
mixture was stirred and refluxed for 7 h at 80 °C under a dinitrogen
atmosphere. During reflux the same amounts of triethylamine and
tert-butyldimethylsilylethyne were added twice (after 2 h 20 min and
4 h 40 min). The solvent was evaporated with a rotary evaporator at
40 °C, and the solid was dissolved in n-hexane and filtered. The
filtrate was purified by column chromatography on silica with n-
hexane/ethyl acetate 9:1 as eluent (Rf = 0.34), yielding a white solid
(94%, 1.1 g, 3.0 mmol). 1H NMR (300 MHz, chloroform-d, 298 K) δ
8.70 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H, T6), 8.59 (dt, J = 8.0, 1.1 Hz, 1H,
T3), 8.49 (s, 1H, T3′), 7.85 (td, J = 7.7, 1.8 Hz, 1H, T4), 7.34 (ddd, J
= 7.5, 4.8, 1.2 Hz, 1H, T5), 1.01 (s, 5H), 0.21 (s, 3H). 13C NMR (75
MHz, chloroform-d, 298 K) δ 155.6 + 155.4 (T2+T2′), 149.1 (T6),
136.9 (T4), 133.3 (T4′), 124.0 (T5), 123.2 (T3′), 121.2 (T4), 103.3
(C-C-Si), 98.03 (Ar-C-C), 26.2 (Si−C-(CH3)3), 16.7 (Si-C-(CH3)3),
−4.7 (Si-(CH3)2). ES MS m/z (calc.): 372.5 (372.2 [M + H]+).
Figure 1. Schematic representation of the ruthenium complexes
[1](PF6)2 and [2](PF6)2.
Scheme 1. Schematic Overview of the Interaction of an Alkyne-Functionalized Ruthenium-Based Drug with Its Biological
Target after Visible Light Activation
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[Ru(RCC-tpy)(Cl)3] (R = TBDMS), [3]. RuCl3·H2O (500 mg, 2.41
mmol) and RCC-tpy (895 mg, 2.41 mmol) were dissolved in ethanol
(250 mL) and refluxed overnight while stirring. The reaction was
cooled down to room temperature and chilled in the freezer
overnight. The precipitate was filtered from the red solution and
washed with cold ethanol and diethyl ether. Drying in vacuo yielded a
brownish red solid that was used without further purification (75%,
1.05 g, 1.82 mmol).
[Ru(RCC-tpy)(bpy)(Cl)]Cl (R = TBDMS), [4]Cl. [Ru(RCC-
tpy)(Cl)3] (100 mg, 0.18 mmol), 2,2′-bipyridine (28 mg, 0.18
mmol), and lithium chloride (41 mg, 0.98 mmol) were dissolved in a
degassed ethanol/water mixture (20 mL, 3:1). Triethylamine (62 μL,
0.45 mmol) was added, and the reaction mixture was stirred at 60 °C
under dinitrogen atmosphere overnight. The reaction mixture was
filtered hot over Celite, and the cake was washed with ethanol. After
evaporation of the combined solvents, the crude mixture was purified
by column chromatography on silica with dichloromethane/methanol
(9:1, Rf = 0.42) as eluent. Evaporation of the solvent yielded [4]Cl as
a dark purple solid (82%, 103 mg, 0.15 mmol). 1H NMR (300 MHz,
methanol-d4, 298 K) δ 10.19 (dd, J = 5.6, 1.6, 0.7 Hz, 1H, A6), 8.79
(dt, J = 8.2, 1.1 Hz, 1H, A3), 8.71 (s, 2H, T3′), 8.61 (dt, J = 8.0, 1.1
Hz, 2H, T3), 8.49 (dd, J = 8.1, 1.2 Hz, 1H, B3), 8.34 (td, J = 7.8, 1.5
Hz, 1H, A4), 8.02 (ddd, J = 7.4, 5.7, 1.3 Hz, 1H, A5), 7.93 (td, J = 7.9,
1.5 Hz, 2H, T4), 7.75 (td, J = 7.8, 1.4 Hz, 1H, B4), 7.69 (ddd, J = 5.5,
1.6, 0.8 Hz, 2H, T6), 7.43−7.28 (m, 3H, T5+B6), 7.05 (ddd, J = 7.3,
5.7, 1.4 Hz, 1H, B5), 1.12 (s, 9H, Si-C-(CH3)3), 0.32 (s, 6H, Si-
(CH3)2).
13C NMR (75 MHz, methanol-d4, 298 K) δ 160.1 + 157.5
(A2+B2), 159.8 + 159.6 (T2+T2′), 153.6 (A6), 153.2 (T6), 153.0
(B6), 138.5 (T4), 138.3 (A4), 137.1 (B4), 129.6 (T4′), 128.8 (T5),
128.2 (A5), 127.6 (B5), 125.6 (T3′), 125.3 (T3), 124.8 (A3), 124.6
(B3), 103.7 + 101.8 (Ar-C-C + C-C-Si), 26.6 (Si-C-(CH3)3), 17.6
(Si-C-(CH3)3), −4.6 (Si-(CH3)2). ES MS m/z (calc.): 664.6 (664.1,
[M − Cl]+).
[Ru(RCC-tpy)(bpy)(Hmte)](PF6)2 (R = TBDMS), [5](PF6)2.
[Ru(RCC-tpy)(bpy)(Cl)]Cl (200 mg, 0.290 mmol) and 2-
(methylthio)ethanol (1.26 mL, 14.5 mmol) were dissolved in
degassed water (40 mL) and reacted at 60 °C under a dinitrogen
atmosphere overnight. After confirmation of reaction completion by
TLC (silica, dichloromethane/methanol 9/1, Rf = 0.28), a saturated
aqueous potassium hexafluorophosphate solution was added. The
precipitate was filtered and rinsed carefully with ice-cold water (10
mL) and diethyl ether (25 mL). Drying in vacuo yielded [5](PF6)2 as
an orange-brown solid (85%, 250 mg, 0.25 mmol). 1H NMR (300
MHz, acetone-d6, 298 K) δ 9.98 (d, J = 5.4 Hz, 1H, A6), 8.99 (s, 2H,
T3′), 8.96 (d, J = 8.1 Hz, 1H, A3), 8.89 (d, J = 8.1 Hz, 2H, T3), 8.72
(d, J = 8.2 Hz, 1H, B3), 8.50 (td, J = 7.9, 1.4 Hz, 1H, A4), 8.28−8.12
(m, 3H, T4+A5), 8.09−7.98 (m, 3H, T6+B4), 7.66 (dd, J = 6.0, 1.0
Hz, 1H, B6), 7.57 (ddd, J = 7.4, 5.6, 1.3 Hz, 2H, T5), 7.31 (ddd, J =
7.3, 5.6, 1.3 Hz, 1H, B5), 4.07 (t, J = 5.1 Hz, 1H, OH), 3.56 (dt, J =
5.1, 5.6 Hz, 2H, S-CH2−CH2), 2.05−1.99 (m, 2H, S−CH2), 1.56 (s,
3H, S−CH3), 1.11 (s, 9H, Si-C-(CH3)3), 0.33 (s, 6H, Si-(CH3)2). 13C
NMR (75 MHz, acetone-d6, 298 K) δ 158.7 + 158.6 (T2 + T2′),
157.7 + 157.6 (A2 + B2), 154.4 (T6), 153.1 (A6), 151.2 (B6), 139.9
(T4), 139.4 (A4), 139.3 (B4), 131.7 (T4‘), 129.9 (T5), 129.0 (A5),
128.3 (B5), 127.1 (T3′), 126.4 (T3), 125.8 (A3), 124.9 (B3), 103.1 +
58.93 (Ar-C-C + C-C-Si), 59.04 (S-CH2-CH2), 37.6 (S-CH2), 26.5
(Si-C-(CH3)3), 17.3 (Si-C-(CH3)3), 14.9 (S-CH3), −4.6 (Si-(CH3)2).
ES MS m/z (calc.): 360.9 (360.6, [M − 2PF6]2+).
[Ru(HCC-tpy)(bpy)(Hmte)](PF6)2, [2](PF6)2. [Ru(RCC-tpy)-
(bpy)(Hmte)](PF6)2 (250 mg, 0.247 mmol) and potassium fluoride
(72 mg, 1.2 mmol) were dissolved in methanol (6 mL) and stirred at
30 °C overnight. The solvent was reduced in volume and a saturated
aqueous potassium hexafluorophosphate solution was added until a
precipitate was formed. The precipitate was filtered and rinsed
carefully with ice-cold water (10 mL) and diethyl ether (25 mL).
Drying in vacuo yielded [2](PF6)2 as an orange solid (76%, 168 mg,
0.187 mmol). 1H NMR (300 MHz, acetone-d6, 298 K) δ 9.97 (ddd, J
= 5.6, 1.6, 0.8 Hz, 1H, A6), 8.99 (s, 2H, T3′), 8.96 (dt, J = 8.1, 1.1 Hz,
1H, A3), 8.88 (ddd, J = 7.8, 1.2, 0.6 Hz, 2H, T3), 8.72 (dt, J = 8.1, 1.1
Hz, 1H, B3), 8.50 (td, J = 7.9, 1.5 Hz, 1H, A4), 8.22 (td, J = 7.9, 1.5
Hz, 2H, T4), 8.19−8.13 (m, 1H, A5), 8.06 (ddd, J = 5.5, 1.5, 0.7 Hz,
2H, T6), 8.06−7.97 (m, 1H, B4), 7.63 (ddd, J = 5.7, 1.5, 0.7 Hz, 1H,
B6), 7.58 (ddd, J = 7.7, 5.5, 1.3 Hz, 2H, T5), 7.30 (ddd, J = 7.2, 5.7,
1.3 Hz, 1H, B5), 4.55 (s, 1H, CCH), 4.06 (t, J = 5.1 Hz, 1H, OH),
3.56 (dt, J = 5.1, 5.7 Hz, 2H, S-CH2-CH2), 2.06−1.97 (m, 2H, S-
CH2), 1.56 (s, 3H, S-CH3).
13C NMR (75 MHz, acetone-d6, 298 K) δ
158.8 + 158.6 (T2 + T2′), 157.7 + 157.6 (A2 + B2), 154.5 (T6),
153.1 (A6), 151.2 (B6), 140.0 (T4), 139.5 (A4), 139.3 (B4), 131.3
(T4′), 129.9 (T5), 129.0 (A5), 128.3 (B5), 127.4 (T3′), 126.4 (T3),
125.8 (A3), 124.9 (B3), 87.9 (CCH), 81.1 (CCH), 59.1 (S-CH2-
CH2), 37.6 (S-CH2), 15.0 (S-CH3). ES MS m/z (calc.): 303.5 (303.6,
[M − 2PF6]2+). High resolution ES MS m/z (calc.): 303.54874
(303 .54881 , [M − 2PF6]2+) . E lem. Anal . Ca lc . for
C30H27F12N5OP2RuS: C, 40.19; H, 3.04; N, 7.81. Found: C, 40.21;
H, 3.06; N, 7.79.
Single Crystal X-ray Crystallography. Single crystals of
[2](PF6)2 were obtained by recrystallization through liquid−vapor
diffusion using acetonitrile as solvent and diisopropyl ether as
countersolvent. In short, 1 mg of [2](PF6)2 was dissolved in 1 mL of
acetonitrile and placed in a small vial. This vial was placed in a larger
vial containing 2.8 mL of diisopropyl ether. The large vial was closed,
and vapor diffusion occurred within a few days to afford X-ray quality
dark red rhombic crystals.
All reflection intensities were measured at 110(2) K using a
SuperNova diffractometer (equipped with Atlas detector) with Cu Kα
radiation (λ = 1.54178 Å) under the program CrysAlisPro (Version
CrysAlisPro 1.171.39.29c, Rigaku OD, 2017). The same program was
used to refine the cell dimensions and for data reduction. The
structure was solved with the program SHELXS-2014/7 (Sheldrick,
2015) and was refined on F2 with SHELXL-2014/7 (Sheldrick, 2015).
Analytical numeric absorption correction using a multifaceted crystal
model was applied using CrysAlisPro. The temperature of the data
collection was controlled using the system Cryojet (manufactured by
Oxford Instruments). The H atoms were placed at calculated
positions using the instructions AFIX 23, AFIX 43, AFIX 137,
AFIX 147, or AFIX 163 with isotropic displacement parameters
having values 1.2 or 1.5 Ueq of the attached C or O atoms. The
structure of [2](PF6)2 is ordered.
Crystal structure data for [2](PF6)2: 0.15 × 0.13 × 0.02 mm
3,
triclinic, P-1, a = 9.9395 (3), b = 11.2670 (3), c = 16.2664 (4) Å, α =
96.662 (2), β = 91.650 (2), γ = 111.580 (2)°, V = 1677.48 (8) Å3, Z =
2, μ = 6.21 mm−1, transmission factor range: 0.485−0.882. 21777
reflections were measured up to a resolution of (sin θ/λ)max = 0.616
Å−1. 6568 reflections were unique (Rint = 0.027), of which 6083 were
observed [I > 2σ(I)]. 471 parameters were refined. R1/wR2 [I >
2σ(I)]: 0.0273/0.0674. R1/wR2 [all refl.]: 0.0305/0.0699. S = 1.026.
Residual electron density found between −0.49 and 0.90 e Å−3.
Photochemistry. Photoreactions monitored with UV−vis were
performed using a Cary 50 Varian spectrometer equipped with
temperature control and a magnetic stirrer. The measurements were
performed in a quartz cuvette, containing 3 mL of solution.
Irradiations were carried out under air atmosphere. Irradiation was
performed from the top of the cuvette perpendicularly to the optical
axis of the spectrometer using a custom-build LED irradiation setup,
consisting of a high-power LED driven by a LED driver operating at
350 mA.
For photoactivation with green light, a LED light source (λ = 517
nm, Δλ1/2 = 23 nm, 5.42 mW, 5.4 × 10−8 mol·s−1) was used, and
absorption spectrum was measured for 70 min at T = 37 °C. [Ru] =
0.130 mM for [1](PF6)2 and 0.074 mM for [2](PF6)2. Data was
analyzed using Microsoft Excel 2010.
Photosubstitution Quantum Yield. For photosubstitution
quantum yield determination for [2](PF6)2 (0.082 mM), a LED
light source (λ = 466 nm, Δλ1/2 = 36 nm, 15.4 mW, 1.11 × 10−7
mol·s−1) was used, and UV−vis absorption spectra were recorded
every 12 s for 30 min at T = 37 °C. Data was analyzed using Microsoft
Excel 2010. The rate constants of the photosubstitution reaction (kΦ)
were derived by fitting the time evolution of the UV−vis absorption at
491 nm to a monoexponential decay function using Origin Pro 9.1. As
the irradiation wavelength was chosen close to the isosbestic point in
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the photosubstitution reactions, A466 was assumed to be constant in
time, so that the obtained rate constants could be converted into












Here, kΦ is the found photochemical rate constant, nRu is the total
amount of ruthenium ions, qp is the incoming photon flux, and A466 is
the absorbance at the irradiation wavelength.
Mass Spectrometry for Ru-BSA Interaction: Sample Prep-
aration. Interactions between the photoactivable ruthenium
compounds and bovine serum albumin were assessed by high-
resolution ESI-MS with slight modifications of the general method
described in the literature.7,63,64 Two stock solutions of [1](PF6)2 and
[2](PF6)2 were prepared in LC-MS grade water to a final
concentration of 10−3 M. Another stock solution of bovine serum
albumin (fatty free, from Sigma-Aldrich) was prepared in LC-MS
grade water at 10−3 M. Appropriate aliquots of these stock solutions
were mixed and diluted with water to a final protein concentration of
100 μM and complex concentrations of 100, 300, or 500 μM. The
reaction mixtures were prepared in duplicate for both ruthenium
compounds; one sample was completely protected from light
exposure and incubated up to 24 h at 37 °C. The other sample was
irradiated for 1 h at 515 nm shaking at 400 rpm and then incubated
for up to 24 h at 37 °C.
ESI-MS. Aliquots were sampled after 2 and 24 h and diluted with
LC-MS water at 10−5 M protein final concentration with the addition
of 0.1% formic acid. Respective ESI-MS spectra were acquired
through direct infusion at a 10 μL min−1 flow rate in a TripleTOF
5600+ high-resolution mass spectrometer (Sciex, Framingham, MA,
U.S.A.), equipped with a DuoSpray interface operating with an ESI
probe. The ESI source parameters were optimized and were as
follows: positive polarity, ionspray voltage floating 5400 V, temper-
ature 50 °C, ion source gas 1 (GS1) 40; ion source gas 2 (GS2) 0;
curtain gas (CUR) 15, declustering potential (DP) 250 V, collision
energy (CE) 10 V. For acquisition, Analyst TF software 1.7.1 (Sciex)
was used, and deconvoluted spectra were obtained by using the Bio
Tool Kit microapplication v.2.2 embedded in PeakView software v.2.2
(Sciex).
ICP-AES. The residual fractions of the reaction mixtures prepared
for the MS analysis (about 0.9 mL) were used for the ICP-AES
determination of the ruthenium bound to the protein, following a
well-established protocol.65,66 The metalated proteins were isolated
using a centrifugal filter device with a cutoff membrane of 10 kDa and
washed several times with LC-MS grade water. The final metal/
protein adducts were recovered by spinning the filters upside down at
3500 rpm for 3 min with 200 μL of water. The samples were
mineralized in a thermoreactor at 90 °C for 8 h with 1.0 mL of HCl
30% Suprapur grade (Merck Millipore). After that, the samples were
diluted exactly to 6.0 mL with Milli-Q water (≤18 MΩ). The
determination of ruthenium content in these solutions was performed
using a Varian 720-ES inductively coupled plasma atomic emission
spectrometer (ICP-AES). The calibration curve of ruthenium was
obtained using known concentrations of a Ru ICP standard solution
purchased from Sigma-Aldrich. Moreover, each sample was spiked
with 1 ppm of Ge used as an internal standard. The wavelength used
for Ru determination was 267.876 nm, whereas for Ge the line at
209.426 nm was used. The operating conditions were optimized to
obtain maximum signal intensity, and between each sample, a rinse
solution containing 1.0 mL of HCl 30% Suprapur grade and 5.0 mL of
ultrapure water was used to avoid any “memory effect”.
F l u o r o p h o r e L a b e l i n g . B S A a n d t r i s ( 3 -
hydroxypropyltriazolylmethyl)amine were purchased from Sigma-
Aldrich, and Alexa Fluor 647 azide as a triethylammonium salt was
purchased from Thermo Fisher (Figure S8).
Click Reaction. BSA (in 1X PBS, 15 μM) was incubated with
[2](PF6)2 (in DMSO, 75 μM) at 37 °C in the dark for 24 h under
constant shaking. After activation with green light (520 nm, 76 J·cm2)
for 1 h, the solution was incubated at 37 °C in the dark for an
additional 24 h. Samples (50 μL) were taken before and after light
activation (6 and 24 h after activation). Dark control samples as well
as negative controls (without complex, without BSA, or without
fluorophore) which were not activated were collected at the same
time points. Samples were stored at −20 °C if not used directly. For
the click reaction, each sample was incubated with an equivalent
amount of click cocktail (50 μL), copper sulfate (6.4 mM), sodium
ascorbate (37.5 mM), tris(3-hydroxypropyltriazolylmethyl)amine
(THPTA) (in DMSO, 1.3 mM), Tris-HCl (100 mM, pH 8.0), and
Alexa Fluor 647 azide (in DMSO, 5 μM)) at rt under gentle shaking
for 1 h in the dark. The click reaction was quenched with an SDS
loading buffer (50 μL) and used immediately for in-gel fluorescence.
Alkyne-substituted vinculin, homopropargylglycine-Vin (Hpg-Vin),
was used as the positive control and prepared by Dr. Can Araman
according to a published procedure.67
Note that electrophoresis was performed in the dark. Two μg of
protein was added to each well of a 15 well 1.5 mm SDS gel at 200 V
for 1 h. Protein concentration of each sample was measured using a
Qubit reader (Thermo Fisher). Fluorescent bands of the SDS gels
were visualized using a BioRad ChemiDoc Touch Imaging System
with Alexa647 filter. Coomassie staining was applied overnight and
destained with the destaining solution (MeOH:water:AcOH; 5:4:1).
■ RESULTS AND DISCUSSION
Synthesis and Characterization. An alkyne-function-
alized analogue of the ruthenium polypyridyl complex
[1](PF6)2 was synthesized by placing the alkyne moiety in
the 4′-position of the tpy ligand. By doing so, the symmetry of
the resulting complex was preserved, while alkyne functional-
ization on any other positions on the ligands would lead to the
formation of several stereoisomers. Since the alkyne-protecting
Scheme 2. Reaction Scheme of the Stepwise Synthesis of [2](PF6)2
a
aConditions: (i) CuI, Pd(PPh3)2Cl2, TBDMS-ethyne, Et3N, 80 °C, N2, 7 h; 95%; (ii) RuCl3, ethanol, 80 °C, 16 h; 75%; (iii) bpy, LiCl, Et3N,
ethanol/water (3:1), 60 °C, 16 h; 83%; (iv) Hmte, water, 60 °C, N2, 16 h, aq. KPF6; 85%; (v) KF, methanol, 30 °C, 16 h, aq. KPF6; 76%.
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triisopropylsilyl (TIPS) group was reported to be difficult to
remove,68 the use of trimethylsilyl (TMS) and tert-
butyldimethylsilyl (TBDMS) was investigated. Both are
known protecting groups for terminal alkynes, but they are
more readily removed compared to TIPS. In our hands, the
TMS protecting group was not stable enough to withstand
subsequent reaction steps, leading to the formation of
undesired byproducts. Therefore, the synthesis of the alkyne-
functionalized ruthenium complex [2](PF6)2 was finally
achieved using the TBDMS group (Scheme 2). The alkyne-
functionalized tpy ligand (RCC-tpy, where R = TBDMS) was
synthesized using a Sonogashira coupling,52 purified by column
chromatography, and the desired product RCC-tpy was
obtained with a yield of 95%. Although ruthenium(II)
precursors can be used, too,53,69 TBDMS was stable enough
to withstand Takeuchi’s classical synthetic route70 toward
[Ru(tpy)(bpy)Cl]Cl complexes, which involves binding of the
terpyridine chelate to a ruthenium(III) precursor, followed by
bipyridine coordination in reducing conditions. RCC-tpy was
hence reacted with ruthenium(III) chloride, to obtain
[Ru(RCC-tpy)(Cl)3]([3]). The reaction with bpy in etha-
nol/water (3:1) yielded the desired ruthenium(II) product
[Ru(RCC-tpy)(bpy)(Cl)]Cl ([4]Cl) in a yield of 83%; in this
classical reaction the reducing of Ru(III) is obtained by the
combined action of triethylamine as electron donor and boiling
ethanol. The chloride ligand was then substituted in a reaction
with Hmte in pure water at 60 °C for 16 h. Precipitation of the
product after the reaction was achieved by addition of
saturated aqueous potassium hexafluorophosphate. Two
singlets at 1.10 and 0.32 ppm in the 1H NMR spectrum in
acetone-d6 (Figure S1) integrating for nine and six protons,
respectively, and the major peak in the MS spectrum at m/z =
360.9 confirmed the stability of the TBDMS protecting group
during ligand exchange and the nature of [Ru(RCC-tpy)-
(bpy)(Hmte)]2+ (calc. m/z = 360.6 for [5]2+). Noteworthy,
when coordination of Hmte was performed at 80 °C, TBDMS
protection was not fully retained, resulting in the formation of
byproducts. Analysis of these byproducts showed that the
ruthenium center can act as a catalyst in the reaction of a
terminal alkyne with alcohol groups (ethanol or Hmte),
leading to the formation of enol ethers (Scheme S1).71 These
findings emphasized that the TBDMS protecting group was
necessary to protect the alkyne as long as the ruthenium center
bears labile ligands or goes through ligand exchange.
Controlled deprotection of the alkyne in [5](PF6)2 was
performed using 5 equiv of potassium fluoride in methanol at
30 °C. 1H NMR in acetone-d6 shows the disappearance of the
two singlets of the protecting TBDMS group concomitant with
the appearance of a new singlet at 4.55 ppm integrating for one
proton, characteristic for the free alkyne (Figure S2). In
combination with mass spectrometry, the successful synthesis
of [Ru(HCC-tpy)(bpy)(Hmte)](PF6)2 ([2](PF6)2, m/z =
303.5; calc. m/z = 303.6 for [2]2+) was confirmed.
Dark red rhombic single crystals of [2](PF6)2 suitable for X-
ray structure determination were obtained through slow vapor
diffusion of diisopropyl ether into a solution of [2](PF6)2 in
acetonitrile (Figure 2). Selected bond lengths and angles are
summarized in Table 1, together with those reported for the
structure of [1](PF6)2.
62 The alkyne bond length (C17C16
= 1.180(4) Å) is comparable with that of published data.53 The
Ru−N bond distances of the tpy as well as of the bpy ligand in
[2](PF6)2 are not significantly different from those in the
nonfunctionalized analogue [1](PF6)2. Hmte is bound via the
sulfur atom with a Ru−S bond distance of 2.3764(6) Å, which
is slightly longer than in [1](PF6)2.
72 Therefore, it can be
concluded that the alkyne moiety has no significant effect on
the geometry of [2](PF6)2 compared to [1](PF6)2.
Photochemistry of [2](PF6)2. [1](PF6)2 is known to be
stable in the dark, while light irradiation initiates the
substitution of the thioether ligand by a water molecule
([6]2+, Scheme 3).62 To test whether alkyne-functionalized
[2](PF6)2 possesses the same photochemical properties, UV−
vis spectra of a solution of [2](PF6)2 in water were recorded.
The absorbance spectrum of [2](PF6)2 in aqueous solution is
characterized by an absorption maximum at 470 nm, and when
kept in the dark, the complex is stable at 37 °C for 16 h
(Figure S4). However, when irradiated with a green LED (517
nm) at 37 °C in water, the UV−vis spectrum of [2](PF6)2
showed a bathochromic shift of the maximum to 491 nm
(Figure 3). This change was accompanied by a change of the
major peaks in MS spectra from m/z = 303.2 ([2]2+, calc. m/z
Figure 2. Displacement ellipsoid (50% probability level) of the
cationic part of [2](PF6)2 as observed in the crystal structure at
110(2) K. Counterions and H atoms have been omitted for clarity.
Table 1. Selected Bond Lengths (Å), Angles (deg), and















aData taken from Bahreman et al.62
Scheme 3. Photosubstitution Reaction of [1](PF6)2 and
[2](PF6)2 in Aqueous Solution
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= 303.6) to m/z = 266.2, indicating the formation of the aqua
complex [Ru(HCC-tpy)(bpy)(OH2)]
2+ ([7]2+, calc. m/z =
266.5, Figure S6). According to mass spectrometry, the
photosubstitution was completed after approximately 30 min
of irradiation, after which no traces of the starting complex
could be observed, while the initial spectrum shows no traces
of the photoproduct (Figure S6). The photosubstitution
quantum yield in water, Φ466, measured by UV−vis spectros-
copy by irradiation near the isosbestic point (466 nm), was
found to be 0.017 at 37 °C(Table 2). This value is slightly
lower than that found for the nonfunctionalized analogue
[1](PF6)2 under blue light irradiation (Φ452 = 0.022).62 In
addition, [1](PF6)2 and [2](PF6)2 show similar low singlet
oxygen generation quantum yields (ΦΔ) and, as expected,
negligible phosphorescence quantum yields ΦP (Table 2,
Figure S7). These results demonstrated that the alkyne moiety
in [2]2+, though slightly lowering the photosubstitution
quantum yield, does not qualitatively alter the photochemical
properties of the complex, compared to [1]2+.
CuAAC Reaction on the Ruthenium Complex. To test
whether the alkyne-functionalization allows for the CuAAC
reaction on the ruthenium complex, [2](PF6)2 was reacted
with an excess of 2-(2-(2-azidoethoxy)ethoxy)ethanol in the
presence of catalytic amounts of Cu(II) and sodium ascorbate
in a water/acetone mixture (9:1) at 25 °C for 1 h (Scheme 4).
MS analysis of the reaction mixture showed peaks centered at
m/z = 391.2 corresponding to the click product [8]2+ (calc.
m/z = 391.1). The signal of the starting material [2]2+ at calc.
m/z = 303.6 had disappeared. After liquid−liquid extraction
from dichloromethane, the 1H NMR spectrum in acetone-d6
showed no singlet peak at 4.56 ppm corresponding to the
terminal alkyne, but a new singlet at 9.04 ppm for triazole
formation was shown (Figure S3). Overall, the CuAAC
reaction on [2](PF6)2 was successful, and full conversion
after a 1-h reaction time was demonstrated.
Investigation of the Interaction between [2]2+ and
BSA. The interaction of [2](PF6)2 and BSA was investigated
by fluorophore-labeling via the CuAAC reaction on the alkyne-
functionalized complex-BSA adduct with an azide-fluorophore
(Alexa Fluor 647 azide, Alexa647, Figure S8) and analyzed by
gel electrophoresis (Figure 4). Incubation of Hmte-protected
[2](PF6)2 (75 μM) with BSA (15 μM) for 24 h at 37 °C in the
dark did not result in a fluorescent signal after the CuAAC
reaction (Figure 4, lane 1), indicating that the protected
complex could not bind to BSA. However, when the mixture
was irradiated with green light (λex = 520 nm) for 1 h and then
further incubated with BSA in the dark for 6 or 24 h, a
fluorescent band appeared between 55 and 70 kDa (Figure 4,
lane 6 for 6 h and lane 12 for 24 h). This result indicated that
(i) light activation of the complex was successful and allowed
for controlling the interaction of the complex with BSA, (ii)
the complex-BSA adduct can be labeled with a fluorophore by
CuAAC, and (iii) adduct formation between the ruthenium
complex and BSA increases over time (quantitatively shown by
elevated levels of fluorescence intensity of the band when
going from a 6- to 24-h incubation time). Several negative
controls were performed, e.g., samples with nonfunctionalized
complex [1](PF6)2 (Figure 4, lanes 3 and 8) or without any
complex (Figure 4, lane 5). These samples did not result in any
significant labeling. A low background fluorescence in lanes 1,
3, 5, 8, 9, 11 was observed due to unspecific binding of the
fluorophore Alexa647 to BSA. Indeed, this was confirmed by
BSA-free controls (Figure 4, lane 4) and fluorophore-free
controls (lanes 2, 7, and 10 in Figure 4), as these did not
exhibit any fluorescence. If not activated, [2](PF6)2 remained
thermally stable for the entire incubation time (Figure 4, lane
13, and Figure S5). Upon increased BSA concentrations, the
intensity of the fluorescent band increased as well (BSA
concentrations vary from 5 to 20 μM, Ru:BSA 5:1, 5:3, and
5:5, Figures S9 and S10). These experiments showed that the
fluorescence intensity of the bands is correlated to the
increased BSA concentration. Thus, the interaction between
[2]2+ and BSA appears to be concentration-dependent.
To further explore the added value of this gel-based method
for studying the BSA-Ru interaction, compared to existing
ones, the interaction between the ruthenium complex [1]2+ or
[2]2+ and BSA was also investigated with UV−vis spectrosco-
py. First, the absorbance spectra of solutions of only the
complexes (15 μM) or BSA (15 μM) were recorded separately
in PBS in the dark for 24 h at 37 °C (Figures S11 and S12).
The unchanged UV−vis spectra indicated the thermal stability
of both individual species. Thereafter, the absorbance spectra
of mixtures of the ruthenium complexes (15 μM) and BSA (15
μM) were recorded under the same conditions. The spectrum
of the solution of [1](PF6)2 and BSA did not change during 24
h, as expected for the Hmte-protected complex (Figure 5a).
Figure 3. Evolution of the UV−vis absorption spectra (region 350−
700 nm) of a solution of [2](PF6)2 in water upon green light
irradiation. Conditions: [Ru] = 0.074 mM, T = 37 °C, light source: λ
= 517 nm, Δλ1/2 = 23 nm, 5.42 mW, photon flux Φ = 5.4 × 10−8 mol·
s−1, V = 3 mL, under air atmosphere. Inset: time evolution of
absorbance at wavelength 491 nm.
Table 2. Maximum Absorption Wavelengths (λmax in nm), Molar Absorption Coefficient (ε in M
−1·cm−1), Phosphorescence
Quantum Yield (ΦP) in Methanol-d6, Singlet Oxygen Generation Quantum Yield (ΦΔ) in Methanol-d6, and Photosubstitution
Quantum Yields in Water (Φmax at 25 °C) for Complexes [2](PF6)2 and [1](PF6)2
λmax
a ελmax
a ΦPb ΦΔb Φmaxa
[2](PF6)2 470 9.54 × 103 <1.0 × 10−4 0.007 0.017
d
[1](PF6)2 450
c 6.60 × 103c <1.0 × 10−4 <0.005 0.022c,e
aIn Milli-Q water. bIn methanol-d6.
cData from Bahreman et al.62 dAt 466 nm, T = 37 °C. eAt 452 nm, T = 24 °C.
Inorganic Chemistry pubs.acs.org/IC Article
https://dx.doi.org/10.1021/acs.inorgchem.0c00742
Inorg. Chem. 2020, 59, 7710−7720
7715
However, when using the aqua complex [6]2+, the UV−vis
spectrum also did not show any change (Figure 5b). Similar
results were obtained when using alkyne-functionalized
complexes [2]2+ and [7]2+ in the presence of BSA (Figure
5c,d). Therefore, it appeared that the interaction between
ruthenium complexes and BSA after light activation cannot be
monitored using UV−vis spectroscopy under the conditions
reported.
Mass spectrometry (MS) is also a very powerful method to
study protein-metallodrug interactions, in particular when the
coordination bonds between the protein residues and the
metal center resist sample preparation and the conditions
inside the MS apparatus.63,73,74 ESI-MS was hence investigated
as a second traditional method to visualize the binding of BSA
to the light-activated ruthenium complex. Different mixtures of
[1](PF6)2 (100, 300, or 500 μM) and BSA (100 μM) in
aqueous solution were incubated at 37 °C for 24 h in the dark
and were activated thereafter with green light (515 nm) for 1
h. Twenty-four h after light activation, samples were subjected
to ESI-MS analysis. The presence of the activated ruthenium
species led to a signal broadening and loss of spectral
resolution compared to BSA only (66,429 Da). However, no
evident signals that can be ascribed to Ru-BSA adducts were
detected. To improve the signal, ultrafiltration with a 10 kDa
cutoff was performed, followed by extensive washing steps.
Upon this treatment, spectra showed a better resolution, but
the signal showed only unreacted BSA. Analysis of the
ultrafiltered fraction by ICP-AES revealed that indeed very
little ruthenium was present in the BSA samples (Table S1).
These results suggest that the interaction between the
ruthenium species and BSA is too weak to be detected by
ESI mass spectrometry. Control experiments with [2](PF6)2
were performed and resulted in similar spectra, indicating that
alkyne functionalization did not cause an enhanced interaction
of the ruthenium center with BSA.
Finally, next to UV−vis spectroscopy and mass spectrom-
etry, tryptophan fluorescence spectroscopy is a common
technique to investigate the interaction of metal complexes
with serum albumin. BSA has two tryptophan residues: one
buried at position 214, and another one at the surface of the
protein at position 131.75 The intrinsic fluorescence of
tryptophan is highly sensitive to the environment, and small
conformational changes, e.g., caused by the interaction of small
molecules with the protein, can lead to the quenching of the
fluorescence. However, complexes [1](PF6)2, [2](PF6)2, and
their corresponding aqua complexes absorb at the excitation
and emission wavelength of BSA (280 and 350 nm,
respectively). Therefore, a visible decrease of the fluorescence
might be due (i) not only to the quenching of the fluorescence
due to complex interactions with the protein but (ii) also to
the absorption of the exciting light by the metal complexes
(filter effect) or (iii) the reabsorption of the fluorescence
emission of the protein by the added complex. Hence,
fluorescence spectroscopy could not be used to study the
interaction between [1]2+ or [2]2+ and BSA.
The chemical biology method developed in this work, which
is based on fluorescent labeling of the metallodrug by click
chemistry after binding to the protein of interest (here BSA),
clearly showed that the light-activated ruthenium complex
interacts with BSA and that this interaction is concentration-
and light-dependent. Thus, the basic idea of metal-based
PACT, that interaction of the ruthenium center with
biomolecules is prevented by coordination of a well-bound
thioether ligand and recovered upon light irradiation, is
validated here for the first time with a protein (BSA). On
the other hand, as no signal of a ruthenated protein was
observed by ESI mass spectrometry, coordination of the BSA
protein to the unprotected ruthenium(II) aqua complex
appears to be too weak to be studied by this technique. Direct
Scheme 4. Reaction Procedure of the CuAAC Reaction of [2](PF6)2 with R-N3 (2-(2-(2-Azidoethoxy)ethoxy)ethanol)
Figure 4. Polyacrylamide gel electrophoresis (PAGE) showing
postlabeled Ru-bound BSA (A). Fluorescence labeling is achieved
via the click reaction with Alexa647. The protecting Hmte ligand of
[2](PF6)2 prevents interaction with BSA, resulting in the absence of
fluorescence labeling (lanes 1, 9, and 13). Light irradiation after 24 h
generates the aqua complex [7]2+ that interacts with BSA after a 6-
and 24-h incubation in the dark after light activation (lanes 6 and 12,
respectively). Control reactions with alkyne-free [1](PF6)2 (lanes 3, 8,
and 11), without Alexa647 (lanes 2, 7, and 10), and without BSA
(lane 4) show no fluorescent labeling. Coomassie staining (B).
Conditions: [Ru] = 75 μM, [BSA] = 15 μM. Green light activation: λ
= 520 nm, light dosage: 76 J/cm2, t = 1 h, T = 37 °C. Click
conditions: 2.5 μM Alexa647, 3.2 mM CuSO4, 18.8 mM NaAsc, 0.7
mM THPTA, 46.3 mM Tris-HCl, t = 1 h, T = 25 °C. Lane 14:
prestained protein ladder, lane 15: positive control: alkyne-substituted
vinculin, homopropargylglycine-Vin.
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coordination of methionine or histidine residues to the
ruthenium complex, as seen with other ruthenium com-
plexes,23,76−80 can also be excluded by the absence of changes
in the UV−vis spectrum of a mixture of the complex and the
protein. In addition to methionine and histidine, BSA contains
35 cysteine residues, forming 17 disulfide bridges. Therefore,
only one thiol group is available for metal binding, Cys34.81
However, the bond between cysteine and ruthenium(II) is
oxygen-sensitive. As demonstrated by our group,82 once
coordinated to [Ru(tpy)(bpy)(OH2)]
2+, cysteine is readily
oxidized in air, which leads to the formation of unstable
sulfenato and sulfinato ruthenium complexes that further
release the hydrolyzed ruthenium complexes [6]2+ and [7]2+
and the sulfinated or sulfenated BSA protein. Since in-gel
fluorescence showed that the intensity of the fluorescent band
corresponding to the ruthenated BSA increased with
incubation time, stable coordination of Cys34 to the metal
can be excluded due to the instability over time of
[Ru(tpy)(bpy)(Cys)]2+ complexes. The last remaining hy-
pothesis that may explain the interaction seen in Figure 4 after
light activation is a combination of, on the one hand, the
noncovalent interaction between the light-activated ruthenium
complex and the hydrophobic core of BSA, similar to what has
been described for KP1019 with HSA,83,84 and, on the other
hand, weak coordination to heteroatom-containing side chains
of the protein, as this interaction does not take place in the
dark. Overall, it is important to realize that (i) the interaction
between the photoactivated aqua complexes [7]2+ and BSA is
weak and (ii) the concentrations necessary for studying this
interaction by the three different techniques used in this work
differ each by almost 1 order of magnitude (Table 3). It is
unclear what the concentrations of ruthenium might be in
biologically relevant conditions and which role such differences
in concentration would play on the thermodynamics and
kinetics of ruthenium binding to BSA. This being said, it
appears that probing the weak interaction between ruthenium
and BSA is possible using the CuAAC-based gel electro-
phoresis method presented here but not using UV−vis or ESI-
MS (Table 3).
■ CONCLUSION
A synthetic route was developed for the functionalization of a
photolabile ruthenium complex [1]2+ with a free alkyne handle.
The TBDMS group appears to be the best protecting group
during ligand introduction and exchange, as it prevents the
formation of side products when a free coordination site
appears on ruthenium near the alkyne group. In addition, the
TBDMS protecting group is easily removed with a small excess
of potassium fluoride, without the need of introducing
bioactive silver ions. The small alkyne handle allowed for
fluorophore postlabeling via CuAAC, which allowed for
studying the interaction between the ruthenium complex
Figure 5. Evolution of the UV−vis spectra (region 250−650 nm) of a solution of a ruthenium complex (0.015 mM) with BSA (0.015 mM) in PBS
under air atmosphere for 24 h at 37 °C: a) [1](PF6)2, b) [6]
2+, c) [2](PF6)2, and d) [7]
2+.
Table 3. Overview of Ru-BSA Interaction Studies
technique concentrationsa result conclusion
PAGE+CuAAC [Ru] = 75 μM fluorescent band after light activation + CuAAC Ru-BSA interaction controlled by light; it withstands
CuAAC conditions[BSA] = 15 μM no fluorescent band in the dark or without click handle
UV−vis [Ru] = 15 μM no change in UV−vis spectrum for activated ruthenium
compound in the presence of BSA
Ru-BSA interaction cannot be visualized by UV−vis
[BSA] = 15 μM
ESI-MS [Ru] = 500 μM no signal of ruthenated BSA Ru-BSA interaction too weak for mass spectrometry
analysis[BSA] = 100 μM
aRu represents either [1](PF6)2 or [2](PF6)2. Conditions: After a 24-h incubation in the dark (37 °C), the samples were activated by 1 h of green
light irradiation at 37 °C and further incubated for at least 24 h.
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[7]2+ and BSA. Importantly, this interaction could not be
detected with traditional methods such as UV−vis spectros-
copy, fluorescence spectroscopy, or ESI mass spectrometry. In
addition, fluorophore postlabeling on a gel also demonstrated
that the thioether ligand effectively protected the ruthenium
complex [1]2+ or [2]2+ from interacting with the BSA protein,
a concept that lies at the core of photoactivated chemo-
therapy.60 Overall, fluorophore labeling via CuAAC on a gel
appears to be an excellent way to visualize weak interactions
between light-activated, nonemissive ruthenium compounds
and proteins such as BSA.
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